Balaz, DavidErick Wikman-Jorgensen, PhilipGiner Galvan, VicenteRubio-Rivas, Manuelde Miguel Campo, BorjaNoureddine Lopez, MariamLopez Caleya, Juan FranciscoGomez Huelgas, RicardoPesqueira Fontan, Paula MariaMendez Bailon, ManuelFernandez-Garces, MarFernandez Cruz, AnaGarcia Garcia, Gema MariaRhyman, NicolasCorral-Gudino, LuisLozano Rodriguez-Mancheno, AquilesNavarro De La Chica, MariaTorregrosa Garcia, AndreaNicolas Alcala, JoseDiaz Jimenez, PabloRoyo Trallero, Leticia EstherComas Casanova, PereMillan Nunez-Cortes, JesusCasas-Rojo, Jose-ManuelSEMI-COVID-19 Network2025-01-072025-01-072021-10-01https://hdl.handle.net/10668/25960Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/COVID-19corticosteroidsSpaincomorbiditiesSarsresearch article34640628open access10.3390/jcm101946102077-0383https://www.mdpi.com/2077-0383/10/19/4610/pdf?version=1633938325757366800024